Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of D...( NAPA Calif. Feb. 6 /- Senetek PLC...),Health

NAPA, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that Dr. Neil Sadick presented on Pyratine-6(TM) at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio, Texas.

In his presentation to the Academy, Dr. Sadick, a prominent New York dermatologist, outlined the therapeutic benefits of Senetek's Pyratine-6(TM) for the treatment of aging skin. Dr. Sadick reviewed clinical data demonstrating the ability of Pyratine-6(TM) to ameliorate the visible signs of skin aging and significantly reduce erythema -- redness of the skin caused by capillary congestion.

In independent clinical trials at the University of California, Irvine and RCTS, an independent laboratory in Irving, Texas, Pyratine-6(TM) demonstrated significant efficacy in the treatment of fine wrinkles, skin roughness, acne lesions, overall skin aging, and significantly reduced erythema as early as two weeks from onset of use. Pyratine-6(TM) was also shown to increase skin moisture content and was well tolerated by all subjects producing no measurable skin irritation or signs of allergic contact dermatitis with twice-daily application over the 12-week study periods.

Frank Massino, Chairman and Chief Executive Officer of Senetek stated, "We are very pleased by the recognition Pyratine-6(TM) has received at this important dermatological symposium."

About Senetek PLC

Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final dev
'/>"/>